ArticleAME case reports2025
Unusual presentation and management of parathyroid carcinoma with pulmonary metastasis: a case report.
Article in AME case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parathyroid carcinoma is a rare and challenging malignancy, often confirmed by histopathological analysis. Due to its rarity, it can present in atypically. We present a case of parathyroid carcinoma with an unusual course of pulmonary metastasis emphasizing the complexities of its diagnosis and management. Case Description: A 38-year-old lady was referred to our department when her newborn was found to have hypoparathyroidism. Laboratory tests showed elevated parathyroid hormone (PTH) and adjusted calcium levels. Imaging studies suggested the presence of parathyroid tumors, and histopathology confirmed parathyroid carcinoma. Immunohistochemistry was positive for GATA3 in the tumor cells, and next generation sequencing revealed CDC73 mutation, MYC rearrangement, ASXL1 mutation, and a tumor mutational burden (TMB) of 11 Muts/Mb. Despite surgical intervention and initial remission, she developed pulmonary metastasis, which was surgically addressed. She is currently under immunotherapy with six cycles of pembrolizumab due to recurrence. Conclusions: This case highlights the importance of prolonged surveillance and imaging for parathyroid carcinoma due to recurrence and metastasis. Aggressive resection of parathyroid carcinoma and metastasis are important to decrease mortality. This case also highlights the importance of genetic factors, like CDC73 mutations, confirmed in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.